Tiny RNA Molecule Emerges as a Promising Biomarker for Diabetic Eye Disease

Diabetic retinopathy remains one of the most feared complications of diabetes, a slow and often silent assault on the delicate blood vessels of the retina that can progress for years before a patient notices anything wrong. By the time blurred vision or floaters appear, the damage may already be advanced and difficult to reverse. Now, a team of researchers in China has reported that a small RNA molecule circulating in the blood could offer clinicians a much earlier warning signal. In a study published in BMC Endocrine Disorders, the investigators found that levels of a microRNA known as miR-362-5p were significantly elevated in patients with diabetic retinopathy compared with diabetic patients whose retinas remained healthy, and that this molecular signature tracked closely with the severity of their disease.

MicroRNAs are short, non-coding RNA molecules, typically only about twenty-two nucleotides long, that do not carry instructions for making proteins. Instead, they act as fine-tuners of gene expression. After being transcribed from the genome and processed into their mature form, microRNAs are loaded into the RNA-induced silencing complex, a molecular machine that scans messenger RNAs for complementary sequences. When a match is found, the complex either destroys the messenger RNA or blocks its translation into protein. A single microRNA can regulate dozens or even hundreds of different target genes, which places these molecules at critical control points in cellular biology, including inflammation, cell proliferation, and the formation of new blood vessels. Because microRNAs are remarkably stable in blood and other body fluids, they have attracted intense interest as potential liquid biopsy markers for diseases ranging from cancer to neurodegeneration.

The research team, led by Huiqing Guo of the Department of Ophthalmology at the First Affiliated Hospital of Henan Medical University, enrolled seventy patients with type 2 diabetes mellitus but no retinopathy and 136 patients with diabetic retinopathy in the clinical portion of the study. The researchers measured miR-362-5p expression and then applied a battery of statistical tools, including receiver operating characteristic curve analysis, logistic regression, and correlation analysis, to determine whether the microRNA could serve as a diagnostic marker and how its levels related to standard clinical measurements. The results were striking: patients with diabetic retinopathy showed clearly upregulated miR-362-5p compared with the diabetes-only group, and the molecule’s levels correlated with fasting blood glucose, two-hour oral glucose tolerance test values, glycated hemoglobin, and best corrected visual acuity measured on the logMAR scale.

Receiver operating characteristic analysis, a standard method for judging diagnostic performance by plotting sensitivity against the false positive rate, indicated that miR-362-5p could function as a candidate diagnostic biomarker for diabetic retinopathy. Perhaps even more intriguingly, the researchers found that miR-362-5p expression rose further in patients with proliferative diabetic retinopathy, the advanced stage of the disease in which abnormal new blood vessels grow on the retinal surface, compared with patients who had the non-proliferative form. This suggests the microRNA may not merely flag the presence of retinopathy but could help clinicians distinguish early disease from the sight-threatening proliferative stage, a distinction that currently often requires detailed retinal imaging and expert interpretation.

To understand what miR-362-5p is actually doing inside retinal tissue, the team turned to the laboratory bench. They built an in vitro model of diabetic retinopathy by exposing human retinal microvascular endothelial cells to high glucose concentrations, mimicking the metabolic stress that these cells endure in patients with poorly controlled diabetes. Retinal microvascular endothelial cells form the inner lining of the tiny vessels that nourish the retina, and their dysfunction is considered a central event in the pathogenesis of diabetic retinopathy. Under chronic high glucose, these cells proliferate abnormally, migrate excessively, release inflammatory signals, and drive the angiogenic sprouting that ultimately produces the fragile, leaky vessels characteristic of proliferative disease.

Using a cell counting kit-8 assay to quantify proliferation, transwell assays to measure cell migration, and enzyme-linked immunosorbent assays to detect secreted signaling molecules, the researchers manipulated miR-362-5p levels in these stressed cells. When they inhibited the microRNA, several pathological behaviors were blunted: the high glucose-facilitated proliferation and migration of the endothelial cells were attenuated, and the release of inflammatory cytokines interleukin-6 and tumor necrosis factor-alpha dropped. Levels of vascular endothelial growth factor and angiopoietin-2, two key drivers of pathological angiogenesis, also fell. In other words, silencing this one microRNA appeared to rein in multiple arms of the vascular damage cascade simultaneously, which is precisely the kind of multi-target effect that microRNA biology predicts.

The mechanistic story deepened when the investigators used bioinformatic analysis to predict downstream targets and then validated the interaction experimentally with a dual-luciferase reporter assay and western blotting. These techniques converged on a single gene: CCND2, which encodes cyclin D2, a protein that drives cells through the G1 phase of the cell cycle and is well known for promoting proliferation. The reporter assay demonstrated that miR-362-5p binds directly to the messenger RNA of CCND2, and western blotting confirmed that the microRNA suppresses cyclin D2 protein production. This finding is biologically coherent: by repressing a cell cycle accelerator, elevated miR-362-5p would be expected to alter endothelial cell behavior, and the study’s functional assays showed that the microRNA’s effects on high glucose-induced injury in the retinal endothelial cells were mediated through this target.

The clinical implications are twofold. First, if miR-362-5p holds up in larger and more diverse cohorts, it could become part of a blood-based screening panel for diabetic retinopathy, allowing ophthalmologists to prioritize patients for retinal imaging and earlier intervention. Current screening relies on periodic dilated eye examinations and retinal photography, which are effective but resource-intensive and dependent on patient compliance, a real challenge given that hundreds of millions of people worldwide now live with diabetes. A circulating biomarker that correlates with glycemic control and visual acuity could add an objective, quantitative dimension to risk stratification. Second, the identification of the miR-362-5p and CCND2 axis suggests a potential therapeutic angle: if inhibiting this microRNA protects retinal endothelial cells from high glucose injury in the laboratory, carefully designed inhibitors might one day complement existing treatments such as anti-VEGF injections for proliferative disease.

The researchers are careful to frame these findings as early-stage. The clinical cohort was drawn from a single institution, the First Affiliated Hospital of Henan Medical University, with ethics approval and written informed consent obtained from all subjects in line with the Declaration of Helsinki, and the mechanistic work was performed entirely in cell culture rather than in animal models or human tissue. MicroRNA biomarkers frequently face hurdles on the road to clinical adoption, including variability in how different laboratories isolate and quantify these molecules from blood, the influence of comorbidities, and the need for standardized reference ranges. The study also reports no external funding, and the authors declare no competing interests, which may reassure readers about the independence of the work.

Nevertheless, the study adds a compelling piece to the rapidly growing puzzle of non-coding RNA involvement in diabetic complications. It links a measurable blood signal to a defined molecular pathway inside the very cells that fail in diabetic retinopathy, and it demonstrates that the pathway can be pharmacologically interrogated with existing laboratory tools. As diabetes rates continue to climb globally, the search for biomarkers that catch retinal damage before vision is lost has become a public health priority. Whether miR-362-5p ultimately earns a place in the clinic will depend on validation studies, but this research provides a clear mechanistic rationale and a concrete starting point for the next phase of investigation into protecting the sight of millions of people with diabetes.

Subject of Research: The role of the microRNA miR-362-5p as a biomarker and mechanistic regulator of diabetic retinopathy

Article Title: The clinical role of miR-362-5p in diabetic retinopathy and its mechanism function in high glucose-induced human retinal microvascular endothelial cells

Article References: Guo, H., Shen, W., Wang, X., Meng, X., & Wang, Y. (2026). The clinical role of miR-362-5p in diabetic retinopathy and its mechanism function in high glucose-induced human retinal microvascular endothelial cells. BMC Endocrine Disorders. https://doi.org/10.1186/s12902-026-02542-1

Image Credits: AI Generated

DOI: 10.1186/s12902-026-02542-1

Keywords: diabetic retinopathy, miR-362-5p, microRNA, CCND2, biomarker, retinal endothelial cells, angiogenesis, inflammation, type 2 diabetes, high glucose, VEGF, diagnostics